Category:

News

mRECIST criteria show greatest accuracy among response assessment models in predicting survival of hepatocellular carcinoma patients receiving transarterial chemoembolization

15 January 2014 - News

mRECIST criteria demonstrate highest survival correlation amongresponse evaluation models after transarterial treatment with drug-eluting beads for hepatocellular carcinoma

30 November 2013 - News

mRECIST criteria reliably differentiate between responders and non-responders in imaging-pathology study oftumor response after transarterial chemoembolization of hepatocellular carcinoma

30 June 2013 - News

mRECIST criteria show greater than 0.95 Goodman-Kruskal γ-values for radiologic-pathologic correlation of hepatocellular carcinoma responseaftertransarterial chemoembolization

15 April 2013 - News

mRECIST criteria exhibit excellentinter- and intra-observer reproducibility in independent blinded assessment of a multicenter clinical trial

15 April 2013 - News

mRECIST response stratify the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib

1 March 2013 - News

Study suggests mRECIST should be used for standard assessment of treatment efficacy in hepatocellular carcinoma patients receiving antiangiogenic drugs

31 January 2013 - News

Sixth Edition of Zakim and Boyer’s HEPATOLOGY, the most famous international textbook of liver disease, endorses mRECIST criteria as a guide to determine response to therapy that is unique to HCC

15 January 2013 - News
0

Study shows mRECIST to be suitable for use with either the 1.0 or the 1.1 standard RECIST models for target lesions assessment in patients with hepatocellular carcinoma

30 November -0001 - News
Previous

1/1

  • 1
Next
2018 © Research Analysis Library srl, via Cocchi 7, IT-56121 Ospedaletto - Pisa, Italy | Email: office@ralweb.com | P.IVA 02181550464